Merlini G,Planté-Bordeneuve V,Judge DP,et al.Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis[J].J Cardiovasc Transl Res,2013,6(6):1 011-1 020.
[2]
Ohya Y,Okamoto S,Tasaki M,et al.Manifestations of transthyretin-related familial amyloidotic polyneuropathy:long-term follow-up of Japanese patients after liver transplantation[J].Surg Today,2011,41(9):1 211-1 218.
[3]
Algalarrondo V,Antonini T,Théaudin M,et al.Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis[J].J Am Coll Cardiol,2015,66(19):2 154-2 156.
[4]
Coelho T,Adams D,Silva A,et al.Safety and efficacy of RNAi therapy for transthyretin amyloidosis[J].N Engl J Med,2013,369(9):819-829.
[5]
Takahashi R,Ono K,Shibata S,et al.Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy(TTR Val30Met)in a Japanese endemic area[J].J Neurol Sci,2014,345(1-2):231-235.
[6]
Cardoso I,Martins D,Ribeiro T,et al.Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers:studies in FAP mouse models[J].J Transl Med,2010,8:74.
[7]
Maurer MS,Grogan DR,Judge DP,et al.Tafamidis in transthyretin amyloid cardiomyopathy:effects on transthyretin stabilization and clinical outcomes[J].Circ Heart Fail,2015,8(3):519-526.
[8]
Yukio A,Yoshiki S,Konen O,et al.Effects of tafamidis treatment on transthyretin(TTR)stabilization,efficacy,and safety in Japanese patients with familial amyloid polyneuropathy(TTR-FAP)with Val30Met and non-Varl30Met:A phaseⅢ,open-label study[J].J Neurol Sci,2016,362:266-271.
Kristen AV,Lehrke S,Buss S,et al.,Green tea halts progression of cardiac transthyretin amyloidosis:an observational report[J].Clin Res Cardiol,2012,101(10):805-813.
[11]
Araki S,Ando Y.Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto,Japan(1967-2010)-[J].Proc Jpn Acad Ser B Phys Biol Sci,2010,86(7):694-706.
[12]
Ebert EC,Nagar M.Gastrointestinal manifestations of amyloidosis[J].Am J Gastroenterol,2008,103(3):776-787.
[13]
Gilbertson JA,Theis JD,Vrana JA,et al.A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue[J].J Clin Pathol,2015,68(4):314-317.
[14]
Benson MD.Liver transplantation and transthyretin amyloidosis[J].Muscle Nerve,2013,47(2):157-162.
[15]
Carvalho A,Rocha A,Lobato L.Liver transplantation in transthyretin amyloidosis:issues and challenges[J].Liver Transpl,2015,21(3):282-292.
[16]
Pullakhandam R,Srinivas PN,Nair MK,et al.Binding and stabilization of transthyretin by curcumin[J].Arch Biochem Biophys,2009,485(2):115-119.
[17]
Yamashita T,Ando Y,Okamoto S,et al.Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy[J].Neurology,2012,78(9):637-643.
[18]
Ericzon BG,Wilczek HE,Larsson M,et al.Liver Transplantation for Hereditary Transthyretin Amyloidosis:After 20Years Still the Best Therapeutic Alternative[J]?Transplantation,2015,99(9):1 847-1 854.
[19]
Ackermann EJ,Guo S,Booten S,et al.Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy[J].Amyloid,2012,19Suppl 1:43-44.
